{
    "clinical_study": {
        "@rank": "61888", 
        "arm_group": {
            "arm_group_label": "HIV (Human Immunodeficiency Virus) positive subjects", 
            "description": "Subjects participating in this purely observational study will be HIV-infected adults, who are currently being treated with Kaletra\u00ae or those who are initiated on treatment with Kaletra\u00ae and willing to be enrolled in the KASA program.\nAll treatments will be as per routine care which will be determined exclusively by the physician and the patient without consideration of the study"
        }, 
        "brief_summary": {
            "textblock": "The study will assess the effectiveness of KASA (Kaletra Patient Support Program) on\n      improving or maintaining treatment adherence in HIV positive patients that have been\n      initiated on treatment with Kaletra\u00ae. This will be a purely observational study conducted on\n      patients that will be on treatment with Kaletra\u00ae. All treatments will be as per routine care\n      including the use of KASA which will be determined exclusively by the physician and the\n      patient without consideration of the study.\n\n      The efficacy of disease management programs as assessed in randomized clinical trials is not\n      representative of real - life effectiveness observed under routine clinical practice. In\n      real - life settings the utilization of and compliance with disease management programs by\n      physicians and patients is not uniform. Therefore assessment of their true effectiveness is\n      ideally conducted under a pure observational setting without any interference from the\n      investigators with respect to making the programs available to patients and enforcing their\n      adherence to them."
        }, 
        "brief_title": "Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Human Immunodeficiency Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a 12-month, multi-center, Canadian Post Marketing Observational Study utilizing a\n      prospective single cohort design.  Patients that are treated with Kaletra\u00ae including those\n      that are initiated on treatment with Kaletra\u00ae will be eligible to participate.  All\n      treatments including participation in the KASA (Kaletra Adherence Support Assistance)\n      program will be according to the decision of the treating physician and the patients and\n      will not be affected in any way by their decision to participate in the study. Follow-up\n      will be for 12 months with visits conducted according to the physician judgment. However,\n      assessments every six months will be recommended."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is HIV+ (positive for Human Immunodeficiency Virus)\n\n          -  On treatment with Kaletra\u00ae or currently initiated on treatment with Kaletra\u00ae.\n\n          -  Has provided written informed consent allowing the use of their data for the study\n             and providing permission for contact by the study personnel.\n\n          -  Willing to be enrolled in the Kaletra Adherence Support Assistance (KASA) program.\n\n        Exclusion Criteria:\n\n          -  Not willing to sign an informed consent.\n\n          -  In the opinion of the treating physician is unlikely to be available for the 12-month\n             follow-up duration of the study.\n\n          -  Is currently participating in a clinical trial of an investigational product.\n\n          -  Not willing to participate in the KASA program."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients will be enrolled from the offices  (at clinic or hospital) of primary care\n        physicians across Canada treating HIV (Human Immunodeficiency Virus) positive patients."
            }
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662336", 
            "org_study_id": "P13-566"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Human Immunodeficiency Virus infection", 
        "lastchanged_date": "April 8, 2014", 
        "link": {
            "url": "http://rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brampton", 
                        "country": "Canada", 
                        "zip": "L6R 3J7"
                    }, 
                    "name": "Site Reference ID/Investigator# 84273"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 84273", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2X 2P4"
                    }, 
                    "name": "Site Reference ID/Investigator# 75441"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75441", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2L 5B1"
                    }, 
                    "name": "Site Reference ID/Investigator# 75437"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75437", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "Site Reference ID/Investigator# 75443"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75443", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H3H 1V1"
                    }, 
                    "name": "Site Reference ID/Investigator# 75442"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75442", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2L 4P9"
                    }, 
                    "name": "Site Reference ID/Investigator# 75444"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75444", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "zip": "K1N 6N5"
                    }, 
                    "name": "Site Reference ID/Investigator# 77613"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 77613", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prince George", 
                        "country": "Canada", 
                        "zip": "V2L 2P6"
                    }, 
                    "name": "Site Reference ID/Investigator# 126514"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 126514", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St-Jerome", 
                        "country": "Canada", 
                        "zip": "J7Z 4B8"
                    }, 
                    "name": "Site Reference ID/Investigator# 122455"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 122455", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "zip": "M5G 1N8"
                    }, 
                    "name": "Site Reference ID/Investigator# 79793"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "zip": "M5B 1L6"
                    }, 
                    "name": "Site Reference ID/Investigator# 107135"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 107135", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "zip": "V6Z 2T1"
                    }, 
                    "name": "Site Reference ID/Investigator# 75439"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75439", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "zip": "V6Z 2C7"
                    }, 
                    "name": "Site Reference ID/Investigator# 75438"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75438", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "zip": "V8W 1M8"
                    }, 
                    "name": "Site Reference ID/Investigator# 75440"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75440", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Real Life Effectiveness of KASA: A Prospective Observational Cohort Study", 
        "overall_contact": {
            "email": "jacinthe.lemay@abbvie.com", 
            "last_name": "Jacinthe  Lemay, PhD", 
            "phone": "514-832-7321"
        }, 
        "overall_contact_backup": {
            "email": "marie-josee.fournelle@abbvie.com", 
            "last_name": "Marie-Josee  Fournelle", 
            "phone": "514-832-7307"
        }, 
        "overall_official": {
            "affiliation": "AbbVie Corporation", 
            "last_name": "Linda  Assouline", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The ASES is a 12 item tool that measures the patient's confidence to undertake treatment related activities and behaviors including medication regimen but also diet and exercise.", 
            "measure": "Adherence will be measured by the Adherence Self - Efficacy Scale (ASES) .The primary outcome measure of the current study will be adherence with KALETRA treatment at 6 months after enrollment in the KASA program.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The QOL 601-2 (\"Health Status Assessment\" ) survey is a brief, comprehensive measure of health-related quality of life used extensively in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS).", 
                "measure": "Change in patient Quality of Life as measured by the QOL 601-2 (Health Status Assessment Questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "From Month 0 to Month 12"
            }, 
            {
                "description": "The Perceived Stress Sale is a 10-item questionnaire that assesses the degree to which the patient considers situations as stressful.", 
                "measure": "Change in patient perception of stress as measured by the Perceived Stress Scale", 
                "safety_issue": "No", 
                "time_frame": "From 0 months to 12 months"
            }, 
            {
                "description": "The CES-D is a 20-item questionnaire assessing the presence of depressive state during the previous week.", 
                "measure": "Change in psychological well-being as measured by the Center for Epidemiologic studies depression scale (CES-D)", 
                "safety_issue": "No", 
                "time_frame": "From 0 months to 12 months"
            }, 
            {
                "description": "CSE is a 13 item questionnaire that measures perceived self-efficacy in coping with daily psychological challenges.", 
                "measure": "Change in Coping Self-Efficacy will be measured the change in the Coping Self - Efficacy Scale (CSE)", 
                "safety_issue": "No", 
                "time_frame": "From 0 months to 12 months"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}